HOUSTON TX., Aug. 23, 2018 /PRNewswire/RadiaDyne®, the innovator of real-time, in vivo, diagnostic radiation patient dose monitoring technology for cancer treatment, and the exclusive manufacturer of the OARtrac® radiation dose monitoring system, was honored to be selected as a finalist for the 55th Annual R&D award.
For the past 55 years, the R&D 100 Awards have served as the most prestigious innovation awards program, honoring R&D pioneers in science and technology. The judging process for the R&D 100 Awards has a singular goal; to pick the 100 most significant new innovations from among the entries each year. Finalists were selected by an independent panel of judges representing R&D leaders in a variety of fields.
Winners will be announced at an awards dinner to be held November 17th in Orlando, Florida.
"We are honored to be selected as a finalist for the prestigious R&D 100 Award, while competing with the most recognizable names in medtech innovation, and it is particularly gratifying when our technology is recognized as a leading innovation by the R&D 100 Awards committee. I am proud of the team behind this technology who strive to offer technology which has the potential to improve radiation delivery and lower side effects for patients undergoing radiation therapy for cancer treatment," said John Isham, Founder and CEO of RadiaDyne.
RadiaDyne® is a privately held diagnostic and medical device company focused on patient dose monitoring and medical device technology to improve cancer treatment outcomes. RadiaDyne® designs and innovates specialized sensor technology and medical treatment devices that assist Radiation Oncologists in delivering radiation dose to the cancerous targets while minimizing damage to the surrounding healthy tissue.
OARtrac® is the first of its kind patient radiation dose monitoring platform which provides gold standard accuracy, real-time physical dose measurement, and proprietary intracavitary delivery devices to measure radiation dose during radiation treatment for cancer. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy with the goal to reduce side effects and offer better clinical outcomes.
link to source: Announcement